Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 324 participants.

Also called NCT07173712

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 324 participants (planned count) (from the registry)
Sponsor
Yanbing Li (from the registry)
Registry
  • NCT NCT07173712
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07173712. Randomized; no masking; primary purpose treatment. Start 2026-03-15 (anticipated); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
Intervention (Drug)
CSII
Intervention (Drug)
Insulin glargine /lixisenatide Fixed Ratio Combination
Intervention (Drug)
Insulin Degludec and Insulin Aspart Injection
Intervention (Drug)
Insulin Glargine (HOE901 - U300)
Intervention (Drug)
Metformin
Lead sponsor
Yanbing Li (class: other)

Record details

Record id
cardio:ct-nct07173712
Content hash
fb4900523ac912fd8f033ce54334af0119279d232ddf6ba419497a908b8ec96d